KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Long-Term Investments: 2009-2011

Historic Long-Term Investments for Teva Pharmaceutical Industries (TEVA) over the last 3 years, with Dec 2011 value amounting to $991.0 million.

  • Teva Pharmaceutical Industries' Long-Term Investments fell 1540.00% to -$164.0 million in Q3 2012 from the same period last year, while for Sep 2012 it was -$164.0 million, marking a year-over-year decrease of 1540.00%. This contributed to the annual value of $991.0 million for FY2011, which is 56.80% up from last year.
  • According to the latest figures from FY2011, Teva Pharmaceutical Industries' Long-Term Investments is $991.0 million, which was up 56.80% from $632.0 million recorded in FY2010.
  • In the past 5 years, Teva Pharmaceutical Industries' Long-Term Investments ranged from a high of $991.0 million in FY2011 and a low of $534.0 million during FY2009.
  • In the last 3 years, Teva Pharmaceutical Industries' Long-Term Investments had a median value of $632.0 million in 2010 and averaged $719.0 million.
  • Data for Teva Pharmaceutical Industries' Long-Term Investments shows a peak YoY skyrocketed of 56.80% (in 2011) over the last 5 years.
  • Yearly analysis of 3 years shows Teva Pharmaceutical Industries' Long-Term Investments stood at $534.0 million in 2009, then increased by 18.35% to $632.0 million in 2010, then spiked by 56.80% to $991.0 million in 2011.